Terms: = Prostate cancer AND FLI1, SIC-1, 2313, ENSG00000151702, Q01543, EWSR2 AND Prognosis
4 results:
1. Transcription factor Fli-1 as a new target for antitumor drug development.
Li L; Yu J; Cheng S; Peng Z; Luo H
Int J Biol Macromol; 2022 Jun; 209(Pt A):1155-1168. PubMed ID: 35447268
[TBL] [Abstract] [Full Text] [Related]
2. Identifying FL11 subtype by characterizing tumor immune microenvironment in prostate adenocarcinoma via Chou's 5-steps rule.
Yang L; Lv Y; Wang S; Zhang Q; Pan Y; Su D; Lu Q; Zuo Y
Genomics; 2020 Mar; 112(2):1500-1515. PubMed ID: 31472243
[TBL] [Abstract] [Full Text] [Related]
3. Overexpression of ETV4 is associated with poor prognosis in prostate cancer: involvement of uPA/uPAR and MMPs.
Qi M; Liu Z; Shen C; Wang L; Zeng J; Wang C; Li C; Fu W; Sun Y; Han B
Tumour Biol; 2015 May; 36(5):3565-72. PubMed ID: 25544710
[TBL] [Abstract] [Full Text] [Related]
4. Expression of urokinase plasminogen activator and receptor in conjunction with the ets family and AP-1 complex transcription factors in high grade prostate cancers.
Gavrilov D; Kenzior O; Evans M; Calaluce R; Folk WR
Eur J Cancer; 2001 May; 37(8):1033-40. PubMed ID: 11334730
[TBL] [Abstract] [Full Text] [Related]
